COST EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS TREATMENT FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FAILURE OF DOCETAXEL USING DATA FROM REAL LIFE TREATMENT PRAXIS IN SWEDEN

被引：1
|
作者：
Persson, U. [1 ]
Nilsson, S. [2 ]
Prutz, C. [3 ]
Hjortsberg, C. [3 ]
机构：
[1] Swedish Inst Hlth Econ, Lund, Sweden
[2] Dept Oncol Pathol, Stockholm, Sweden
[3] Janssen Cilag AB, Sollentuna, Sweden
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.655
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A134 / A135
页数：2
相关论文
共 50 条
  • [21] COST EFFECTIVENESS ANALYSIS COMPARING ENZALUTAMIDE, ABIRATERONE PLUS PREDNISONE AND CABAZITAXEL PLUS PREDINSONE FOR THE TREATMENT OF VISCERAL METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) POST DOCETAXEL FAILURE
    Barqawi, Y.
    Borrego, M.
    Roberts, M.
    Abraham, I
    VALUE IN HEALTH, 2019, 22 : S75 - S75
  • [22] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [23] REANALYSIS OF COST-EFFECTIVENESS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN JAPAN USING A JAPANESE CLAIM DATA SET
    Shibahara, H.
    Shiroiwa, T.
    Tange, C.
    Nakamura, K.
    Ozono, S.
    Shimozuma, K.
    VALUE IN HEALTH, 2014, 17 (03) : A85 - A86
  • [24] Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis
    Oyman, Abdilkerim
    Basak, Mustafa
    Ozcelik, Melike
    Ozyukseler, Deniz Tataroglu
    Isik, Selver
    Yildirim, Mahmut Emre
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (05) : E201 - E207
  • [25] ABIRATERONE ACETATE VERSUS ENZALUTAMIDE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY: COST EFFECTIVENESS ANALYSIS
    He, J.
    Li, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A411
  • [26] Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    Sternberg, C. N.
    Molina, A.
    North, S.
    Mainwaring, P.
    Fizazi, K.
    Hao, Y.
    Rothman, M.
    Gagnon, D. D.
    Kheoh, T.
    Haqq, C. M.
    Cleeland, C.
    de Bono, J. S.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1017 - 1025
  • [27] Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
    Goudarzi, Zahra
    Lotfi, Farhad
    Najafpour, Zhila
    Hafezi, Aliakbar
    Zakaria, Marzieh Alizadeh
    Keshavarz, Khosro
    BMC UROLOGY, 2024, 24 (01)
  • [28] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [29] Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
    Zahra Goudarzi
    Farhad Lotfi
    Zhila Najafpour
    AliAkbar Hafezi
    Marzieh Alizadeh Zakaria
    Khosro Keshavarz
    BMC Urology, 24
  • [30] Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, Frederik Birkebaek
    Roder, Martin Andreas
    Rathenborg, Per
    Brasso, Klaus
    Borre, Michael
    Iversen, Peter
    SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (03) : 268 - 275
12345